Open Access
Article
Lipogenic effects of psychotropic drugs: focus on the SREBP system
Johan Ferno1,Silje Skrede1,Audun Osland Vik-Mo1,Goran Jassim1,Stephanie Le Hellard1,Vidar Martin Steen1
1
Department of Clinical Medicine, Dr Einar Martens' Research Group for Biological Psychiatry and Bergen Mental Health Research Center, University of Bergen, Bergen, Norway. johan.ferno@uib.no
DOI: 10.2741/3675 Volume 16 Issue 1, pp.49-60
Published: 01 January 2011
Abstract

Antipsychotics, antidepressants and mood stabilizers are psychotropic drugs widely used in the treatment of psychiatric disorders, such as schizophrenia, bipolar disorder and major depressive disorder. Such drugs have been used since the early 1950s, and it is now well established that they target neurotransmitter receptors and/or transporters located on central nervous system (CNS) neurons. However, their mechanism of action is still not fully understood, and there is large inter-individual variation in therapeutic response. Psychotropic drugs are also associated with numerous adverse effects, of which weight gain and metabolic disturbances have gained increased focus during the last decade. Based on studies in cultured cells, we have demonstrated that several psychotropic drugs upregulate the expression of genes involved in cellular fatty acid and cholesterol biosynthesis, controlled by the SREBP transcription factors. Lipogenic effects were also observed in vivo, in rat liver and in lymphocytes from drug-treated patients. These results provide new insight into the molecular mechanisms of psychotropic drug action and could be relevant both for their therapeutic action and metabolic adverse effects.

Share and Cite
Johan Ferno, Silje Skrede, Audun Osland Vik-Mo, Goran Jassim, Stephanie Le Hellard, Vidar Martin Steen. Lipogenic effects of psychotropic drugs: focus on the SREBP system. Frontiers in Bioscience-Landmark. 2011. 16(1); 49-60.